{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:03:45Z","timestamp":1788264225488,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T00:00:00Z","timestamp":1501804800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s12325-017-0592-x","type":"journal-article","created":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T11:03:59Z","timestamp":1501844639000},"page":"2083-2092","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization"],"prefix":"10.1007","volume":"34","author":[{"given":"Mehul R.","family":"Dalal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood","family":"Kazemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,4]]},"reference":[{"key":"592_CR1","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2337\/dc12-0413","volume":"35","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364\u201379.","journal-title":"Diabetes Care"},{"key":"592_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140\u20139.","journal-title":"Diabetes Care"},{"key":"592_CR3","unstructured":"Sanofi US, Inc. Press Release. Sanofi receives FDA approval of once-daily basal insulin Toujeo\u00ae. February 25, 2015. \n                    http:\/\/www.news.sanofi.us\/2015-02-25-Sanofi-Receives-FDA-Approval-of-Once-Daily-Basal-Insulin-Toujeo\n                    \n                  . Accessed July 13, 2015."},{"key":"592_CR4","unstructured":"Novo Nordisk Inc. Press Release. Novo Nordisk receives FDA approval for Tresiba\u00ae (insulin degludec injection) for adults with type 1 and type 2 diabetes. September 25, 2015. \n                    http:\/\/press.novonordisk-us.com\/2015-09-25-Novo-Nordisk-Receives-FDA-Approval-for-Tresiba-insulin-degludec-injection-for-Adults-with-Type-1-and-Type-2-Diabetes\n                    \n                  . Accessed January 19, 2016."},{"key":"592_CR5","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1007\/s00125-007-0599-y","volume":"50","author":"UK Hypoglycaemia Study Group","year":"2007","unstructured":"UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140\u20137.","journal-title":"Diabetologia"},{"key":"592_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00592-014-0698-4","volume":"52","author":"P Rys","year":"2015","unstructured":"Rys P, Wojciechowski P, Rogoz-Sitek A, et al. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetol. 2015;52:649\u201362.","journal-title":"Acta Diabetol"},{"key":"592_CR7","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1185\/03007995.2013.811403","volume":"29","author":"KL Davis","year":"2013","unstructured":"Davis KL, Tangirala M, Meyers JL, Wei W. Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy. Curr Med Res Opin. 2013;29:1083\u201391.","journal-title":"Curr Med Res Opin"},{"key":"592_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/dom.12407","volume":"17","author":"P Levin","year":"2015","unstructured":"Levin P, Wei W, Miao R, et al. Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data. Diabetes Obes Metab. 2015;17:245\u201353.","journal-title":"Diabetes Obes Metab"},{"key":"592_CR9","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/dom.12472","volume":"17","author":"MC Riddle","year":"2015","unstructured":"Riddle MC, Yki-J\u00e4rvinen H, Bolli GB, et al. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300\u00a0U\/ml compared with 100\u00a0U\/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension. Diabetes Obes Metab. 2015;17:835\u201342.","journal-title":"Diabetes Obes Metab"},{"key":"592_CR10","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/dom.12532","volume":"17","author":"H Yki-J\u00e4rvinen","year":"2015","unstructured":"Yki-J\u00e4rvinen H, Bergenstal RM, Bolli GB, et al. Glycaemic control and hypoglycaemia with new insulin glargine 300\u00a0U\/mL versus glargine 100\u00a0U\/mL in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension. Diabetes Obes Metab. 2015;17:1142\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"592_CR11","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1089\/dia.2014.0268","volume":"17","author":"J Krall","year":"2015","unstructured":"Krall J, Gabbay R, Zickmund S, Hamm ME, Williams KR, Siminerio L. Current perspectives on psychological insulin resistance: primary care provider and patient views. Diabetes Technol Ther. 2015;17:268\u201374.","journal-title":"Diabetes Technol Ther"},{"issue":"10 Suppl.","key":"592_CR12","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.amjmed.2014.07.003","volume":"127","author":"S Edelman","year":"2014","unstructured":"Edelman S, Pettus J. Challenges associated with insulin therapy in type 2 diabetes mellitus. Am J Med. 2014;127(10 Suppl.):S11\u20136.","journal-title":"Am J Med"},{"key":"592_CR13","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1464-5491.2012.03605.x","volume":"29","author":"M Peyrot","year":"2012","unstructured":"Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29:682\u20139.","journal-title":"Diabet Med"},{"key":"592_CR14","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2337\/diacare.25.2.330","volume":"25","author":"A Wright","year":"2002","unstructured":"Wright A, Burden AC, Paisey RB, Cull CA, Holman RR, UK Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6\u00a0years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330\u20136.","journal-title":"Diabetes Care"},{"key":"592_CR15","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577\u201389.","journal-title":"N Engl J Med"},{"key":"592_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4158\/EP13159.OR","volume":"20","author":"W Wei","year":"2014","unstructured":"Wei W, Pan C, Xie L, Baser O. Real-world insulin treatment persistence among patients with type 2 diabetes. Endocr Pract. 2014;20:52\u201361.","journal-title":"Endocr Pract"},{"key":"592_CR17","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00592-015-0727-y","volume":"52","author":"F Pistrosch","year":"2015","unstructured":"Pistrosch F, Ganz X, Bornstein SR, Birkenfeld AL, Henkel E, Hanefeld M. Risk of and risk factors for hypoglycemia and associated arrhythmias in patients with type 2 diabetes and cardiovascular disease: a cohort study under real-world conditions. Acta Diabetol. 2015;52:889\u201395.","journal-title":"Acta Diabetol"},{"key":"592_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.18553\/jmcp.2015.21.3.243","volume":"21","author":"S Kachroo","year":"2015","unstructured":"Kachroo S, Kawabata H, Colilla S, et al. Association between hypoglycaemia and fall-related events in type 2 diabetes mellitus: analysis of a US commercial database. J Manag Care Spec Pharm. 2015;21:243\u201353.","journal-title":"J Manag Care Spec Pharm"},{"key":"592_CR19","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.2337\/dc11-2054","volume":"35","author":"RG McCoy","year":"2012","unstructured":"McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012;35:1897\u2013901.","journal-title":"Diabetes Care"},{"key":"592_CR20","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/dme.12123","volume":"30","author":"HK Tan","year":"2013","unstructured":"Tan HK, Flanagan D. The impact of hypoglycaemia on patients admitted to hospital with medical emergencies. Diabet Med. 2013;30:574\u201380.","journal-title":"Diabet Med"},{"key":"592_CR21","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/(SICI)1096-9136(199805)15:5<398::AID-DIA595>3.0.CO;2-B","volume":"15","author":"AJ Jaap","year":"1998","unstructured":"Jaap AJ, Jones GC, McCrimmon RJ, Deary IJ, Frier BM. Perceived symptoms of hypoglycaemia in elderly type 2 diabetic patients treated with insulin. Diabet Med. 1998;15:398\u2013401.","journal-title":"Diabet Med"},{"key":"592_CR22","first-page":"673","volume":"17","author":"BJ Quilliam","year":"2011","unstructured":"Quilliam BJ, Simeone JC, Ozbay AB, Kogut SJ. The incidence and costs of hypoglycemia in type 2 diabetes. Am J Manag Care. 2011;17:673\u201380.","journal-title":"Am J Manag Care"},{"key":"592_CR23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.18553\/jmcp.2015.21.3.220","volume":"21","author":"K Bell","year":"2015","unstructured":"Bell K, Parasuraman S, Raju A, Shah M, Graham J, Denno M. Resource utilization and costs associated with using insulin therapy within a newly diagnosed type 2 diabetes mellitus population. J Manag Care Spec Pharm. 2015;21:220\u2013228a.","journal-title":"J Manag Care Spec Pharm"},{"key":"592_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/01.jom.0000161727.03431.3e","volume":"47","author":"GG Rhoads","year":"2005","unstructured":"Rhoads GG, Orsini LS, Crown W, Wang S, Getahun D, Zhang Q. Contribution of hypoglycemia to medical care expenditures and short-term disability in employees with diabetes. J Occup Environ Med. 2005;47:447\u201352.","journal-title":"J Occup Environ Med"},{"key":"592_CR25","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1377\/hlthaff.2010.0666","volume":"29","author":"NA Dreyer","year":"2010","unstructured":"Dreyer NA, Tunis SR, Berger M, Ollendorf D, Mattox P, Gliklich R. Why observational studies should be among the tools used in comparative effectiveness research. Health Aff (Millwood). 2010;29:1818\u201325.","journal-title":"Health Aff (Millwood)"},{"key":"592_CR26","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.2337\/dc12-1205","volume":"35","author":"B Zinman","year":"2012","unstructured":"Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-na\u00efve patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35:2464\u201371.","journal-title":"Diabetes Care"},{"key":"592_CR27","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/dom.12438","volume":"17","author":"GB Bolli","year":"2015","unstructured":"Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300\u00a0U\/ml compared with glargine 100\u00a0U\/ml in insulin-na\u00efve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17:386\u201394.","journal-title":"Diabetes Obes Metab"},{"key":"592_CR28","first-page":"40","volume":"2012","author":"EQ Wu","year":"1995","unstructured":"Wu EQ, Zhou S, Yu A, et al. Outcomes associated with post-discharge insulin continuity in US patients with type 2 diabetes mellitus initiating insulin in the hospital. Hosp Pract (1995). 2012;40:40\u20138.","journal-title":"Hosp Pract (1995)"},{"key":"592_CR29","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s13300-014-0065-z","volume":"5","author":"H Ascher-Svanum","year":"2014","unstructured":"Ascher-Svanum H, Lage MJ, Perez-Nieves M, et al. Early discontinuation and restart of insulin in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2014;5:225\u201342.","journal-title":"Diabetes Ther"},{"key":"592_CR30","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3810\/pgm.2012.01.2525","volume":"124","author":"M Bron","year":"2012","unstructured":"Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med. 2012;124:124\u201332.","journal-title":"Postgrad Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0592-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-017-0592-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0592-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T14:21:45Z","timestamp":1548080505000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-017-0592-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,4]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["592"],"URL":"https:\/\/doi.org\/10.1007\/s12325-017-0592-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,4]]},"assertion":[{"value":"31 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2017","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}